Survival Benefit of Screening for Early Esophageal Carcinoma in Head and Neck Cancer Patients

Abstract: Primary cancer of the head and neck was diagnosed in 676 cases. Systematic endoscopic screening of the upper gastrointestinal tract (including iodine staining of the esophagus) was performed within 1 month of diagnosing head and neck cancer in order to determine the possible presence of a second malignancy- We divided cases in which esophageal cancer was detected into a group in which the initially diagnosed head and neck cancer had been treated curatively and those in which the treatment had been non-curative. A pathological diagnosis of primary esophageal cancer was obtained in 37 cases (5.5%). The incidence of esophageal cancer associated with cancer of the oral cavity or pharynx was significantly higher (10.9%) than in cases with an associated cancer of the larynx or paranasal sinus (1.9%, p<0.05). All but one of the 37 cases detected by screening were asymptomatic and had superficial carcinoma. Of these lesions, 19 Were mucosal carcinomas, 17 submucosal carcinomas and only one an advanced cancer. Twenty-four of these 37 cases had died. The cause of death was head and neck cancer in 17, esophageal cancer in two and other causes in five. The 5-year survival rate of cases in whom the initial head and neck cancer had been treated curatively was 46.7%. The risk of synchronous esophageal cancer associated with cancer of the head and neck is high. Early detection of esophageal cancer at the time of diagnosing cancer of the head and neck and treatment at an early stage is a new strategy for improving the long-term outcome of cases with head and neck cancers associated with esophageal cancer.     

Electronic-endoscopic Observation of ET-1 Induced Mucosal Ischemia and Preventive Effect of ETA Recepter Selective Antagonist,FR139317, in Rat Distal Colon

For investigation of the effects of Endothelin-1 (ET-1) on colonic mucosa, ET-1 (10–160 nmol/kg) was sprinkled on rat colonic mucosa under observation with a new electronic endoscopic system (TOSHIBA TRE-3000, Japan). A high dose of ET-1 induced complete obstruction of submucosal arterioles, but not venules, without affecting arterial blood pressure. The ET-1 -induced contraction of both vessel types was maintained for 50 min and was followed by intramucosal dot hemorrhages. In this experimental model, the effects of ET-1 on the mucosal microcirculation were further analyzed with a laser doppler blood flowmeter (LDF) during endoscopic observation. The maximum decrease in mucosal blood flow was to 20 % of the control value and this decrease was maintained for 20 min at a dose of 80 nmol/kg. An ETA receptor selective antagonist, FR139317 (800 nmol/kg), inhibited ET-1 -induced changes in endoscopic findings and LDF, shifting the concentration-response curve of LDF to the right. FR139317 is a potentially useful new therapy for inflammatory bowel diseases, conditions which have been reported to be associated with high local concentrations of ET-1. Our electronic-endoscopic system was demonstrated to be a useful basic research tool for studying gastrointestinal pathophysiology.